Felix Hasler Klinische Forschung HRC Zürich The Creation of Psychopharmacology III David Healy, Harvard University Press, 2002
Aug 04, 2015
Felix HaslerKlinische Forschung
HRC Zürich
The Creation ofPsychopharmacology III
David Healy, Harvard University Press, 2002
Von den Neuroleptika zu den Antipsychotica
Pipamperone (Dipiperon®)
Risperidon (Risperdal®)1993
Von den Neuroleptika zu den Antipsychotica
Lundbeck: Sertindol (Serdolect® 1996)
Komplikation: Verlängerung des QT-Intervalls
Exkurs Herzphysiologie
Sertindol (Serdolect® 1996)
Komplikation: Verlängerung des QT-Intervalls
Positive symptoms Negative symptoms
Cognitive symptoms Behavioral symptoms
„EGO-DISORDER“
Positive and negative schizophrenia
Thalamus
Frontal Cortex
Striatum Pallidum
Prim.-sensori.Cortex
Extro-ceptive& intro-ceptive Stimuli
CSTC-Loop and Sensorimotor Gating
Hippocampus
-Glu
RA
+5-HT +5-HT +5-HTVTA
+DA-DA
Parietal cortex
Temporal cortex
C. m.
Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, Zipursky RB, Kapur S (2007) Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response - adouble-blind PET study in schizophrenia. Neuropsychopharmacology 32: 1209-15
D2-Besetzung durch Neuroleptika und klinische Wirksamkeit I
Fluoxetin (Prozac®)Klassischer SSRI(Selektiver Serotonin-Wiederaufnahme-Hemmer)
„Symbol of the 90ies“
Figure 2. Mean Standardized Improvement as a Function of Initial Severity and Treatment Group.Drug improvement is portrayed as red triangles around their solid red regression line and placebo improvement as blue circles around their dashed blue regression line; the green shaded area indicates the point at which comparisons of drug versus placebo reach the NICE clinicalsignificance criterion of d ¼ 0.50. Plotted values are sized according to their weight in analyses.
Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug AdministrationKirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, et al., PLoS Medicine Vol. 5, No. 2, e45 doi:10.1371/journal.pmed.0050045
Figure 3. Mean Standardized Improvement as a Function of Initial Severity and Treatment Group, Including Only Trials Whose Samples Had High Initial Severity Drug improvement is portrayed as red triangles around their solid red regression line and placebo improvement as blue circles around their dashed blue regression line; the green shaded area indicates the point at which comparisons of drug versus placebo reach the NICE clinical significance criterion of d ¼ 0.50. Plotted values are sized according to their weight in analyses.doi:10.1371/journal.pmed.0050045.g003
Neue Allianzen
„Management of behaviour“